Honorary Senior Research Fellow
University of Sydney
Dr Chia-chi Liu (BSc, MSc, PhD) is an Honorary Senior Research Fellow in University of Sydney, Australia. Dr Liu is a molecular biologist and biomedical scientist with more than 10 years academic research experiences in the field of cardiovascular disease and cancer-related cardiac dysfunction. She received her MSc in Cell and Molecular Biology at Taipei Medical University, Taiwan; Msc in Biotechnology at University of New South Wales Australia, and her PhD in Chemistry and Biomolecular Science at Macquarie University, Australia. Dr Liu has a strong interest and commitment in drug development/discovery in relation to translational research. Her research initially had been focused on redox signaling in Na+ pump regulation and b3 adrenergic receptors (b3-ARs) in Na pump regulation and heart failure treatment. The work had published in many journals (Circulation; European Heart Journal, etc) and awarded grants with positive outcomes in phase II Clinical Trials. Unteil recently, she has discovered that FXYD membrane proteins could modify Na pump function by relieving the oxidative modification induced Na pump inhibition. In lieu of this, Dr Liu has designed a mutant FXYD protein and established its ability to displace overexpressed FXYD proteins which protect cancer cells against treatments in breast, prostate and pancreatic cancers. A translational outcome of this discovery is that the mutant FXYD peptides can be used as an add-on therapy with existing cancer treatments that results in the reduction of the maximal effective dose of chemotherapy drugs and radiation needed to maintain anticancer efficacy and further alleviate their adverse effects.
Dr Liu’s Research Interests are to translate fundamental molecular discoveries made in the laboratory, into novel pharmaceutical therapies and treatment strategies for heart failure; to establish novel oxidative stress biomarkers to diagnose and monitor the progression of cardiovascular disease and diabetics; and to pioneer therapeutic proteins to improve cancer treatments.